Inhalon Biopharma
Inhaled Immunotherapy for Acute Respiratory Infections
Latest News
July 22, 2021
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read more
July 16, 2021
Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read more
May 26, 2021
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-Trapping” Antibody for the Treatment of COVID-19 Read more
Recent Publications
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R Lai SK, Advanced Drug Delivery Reviews, Feb 2021.